Journal Logo

Simultaneous Sessions I: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical

S103 OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS, LYMA-101 TRIAL - A LYSA TRIAL

Legouill, S.1; Beldi-Ferchiou, A.2; Cacheux, V.3; Alcantara, M.4; Salles, G.5; Canioni, D.4; Bodet-Milin, C.1; Delwail, V.6; Gastinne, T.1; thieblemont, C.7; Moles, M.-P.8; Damaj, G.9; Jaccard, A.10; Daguindau, N.11; Ribrag, V.12; Delfau-Larue, M.-H.13; Macintyre, E.14; Hermine, O.4

Author Information
doi: 10.1097/01.HS9.0000558632.47592.16
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.